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Abstract Molecular cloning of bovine adrenal medulla (AM) 
and pituitary (Pit) a:antichymotrypsin cDNAs indicated novel 
isoforms of ACT. The deduced primary sequences indicated that 
the AM ACT and Pit ACT possess COOH-terminal reactive-site 
domains that are characteristic of serpins (serine protease inhib- 
itors). Of high interest was the finding of unique reactive sites 
within AM ACT and Pit ACT which are predicted to possess Arg 
as P1 residue. Arginine as P1 residue parallels the cleavage spec- 
ificity of neuroendocrine prohormone processing enzymes cleav- 
ing at basic residues. Furthermore, RT-PCR indicated tissue- 
specific expression of AM and Pit ACT mRNAs. The AM and 
Pit isoforms of ACT may regulate novel target proteases involved 
in neuroendocrine function. 
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1. Introduction 
Alphal-antichymotrypsin (ACT), a member of the serpin 
family of protease inhibitors, functions in plasma as a major 
acute phase protein whose levels are rapidly elevated in trau- 
matic events including surgery [1], burn injuries [2,3], cancer [4], 
and disease [5]. More recently, evidence for neuroendocrine 
functions of ACT have been demonstrated. ACT is present in 
amyloid plaques of Alzheimer's Disease brains [6,7]. ACT is 
present within neurosecretory vesicles where it may potently 
inhibit a candidate prohormone processing enzyme known as 
PTP [8]. 
The structure of human liver ACT, deduced from the corre- 
sponding cDNA [9], indicates the presence of a reactive site 
domain in the COOH-terminal region of the protein, which is 
characteristic of members of the serpin family. Selectivity of 
ACT and other serpins for inhibiting target proteases i deter- 
mined, in large part, by the reactive-site domain that contains 
the P1-PI' cleavage site [10,11]. It is known that the P~ residue 
of the serpin resembles the cleavage specificity of the inhibited 
protease. Mutagenesis studies directed at altering the P~ residue 
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of ACT have demonstrated the importance of the Pl residue in 
determining the specific protease that is inhibited [12]. There- 
fore, the P1 residue may predict inhibited proteases based on 
parallel cleavage specificities. 
The cloned liver ACTs in human [13] and bovine [9] have 
generally been thought o resemble ACT present in brain and 
endocrine tissues. However, recent characterization f a bovine 
pituitary ACT-like protein that inhibits a prohormone process- 
ing enzyme suggested that it was not identical to human liver 
ACT, since the pituitary ACT showed differential inhibitory 
potency and less sensitivity to detection by anti-ACT serum 
when compared to the liver ACT [9]. In addition, the existence 
of heterogeneous forms of ACT is supported by the presence 
of multiple bovine ACT genes in Southern analysis [9]. 
The goal of this study was to identify possible neuroendo- 
crine isoforms of bovine ACT through sequence analysis of 
bovine AM and Pit ACT cDNAs that include the reactive-site 
domain. Molecular cloning of AM and Pit ACT cDNAs yielded 
clones possessing reactive-site domains with unique P1 residues 
that differ from previously identified forms of ACT. These 
results demonstrate hat neuroendocrine tissues express novel 
forms of ACT, suggesting regulation of target proteases in 
neuroendocrine function. 
2. Experimental 
2.1. RNA isolation 
Total RNA was isolated from fresh bovine adrenal medulla, pitui- 
tary, and liver by the procedure ofChromoczynski [14]. One gram fresh 
tissue was minced, pulverized in liquid N2, and solubilized in 10 ml of 
4.0 M guanidinium thiocyanate, 25mM sodium citrate, pH 7.0, 0.1 M 
fl-mercaptoethanol, and 0.5% N-sarkosyl. After addition of 2.0 M so- 
dium acetate, pH 4.0 (1 ml) and phenol/chloroform extraction (by 
vortexing with 10 ml phenol and 2 ml chloroform/IAA 49/1 vol/vol, 
incubation at 4°C for 15 min, and centrifugation at 10,000 × g for 20 
min), RNA in the aqueous phase was precipitated byisopropanol and 
resuspended in 10 ml Tris-HC1, 0.5 mM EDTA. Isolation of 
poly(A+)RNA utilized oligo(dT) affinity chromatography, as described 
previously [9,15]. 
2.2. Molecular cloning of bovine AM and Pit ACT cDNAs 
Bovine AM and Pit cDNA libraries were constructed in the lambda 
UniZAPXR vector (Stratagene), as described previously [15]. Molecu- 
lar cloning of ACT cDNAs from bovine adrenal medulla nd pituitary 
was accomplished by screening 1× 106 recombinants from respective 
cDNA libraries with the bovine liver L-1 ACT cDNA (clone pHHKI i), 
isolated by this laboratory [9]. The 32p-labeled liver L-1 ACT cDNA 
(0.9 kb) (labeled by nick translation, according to the protocol by BRL) 
was hybridized to filter lifts of cDNA libraries in 6 × SSC, 5 × Denhardt's 
solution, 0.5% SDS, and 10 mg/ml salmon sperm DNA, at 60°C over- 
night. Filters were washed twice in 2× SSC, 0.1% SDS for 30 min at 
60°C, and twice in 0.1× SSC, 0.5% SDS for 20 rain at room tempera- 
ture. After 34  rounds of screening, a single clone was obtained from 
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each cDNA library. In vivo excision yielded the cDNAs in Bluescript 
KS-plasmid vector (according to the Stratagene protocol). DNA se- 
quencing of both strands of the cDNAs was performed by the dide- 
oxynucleotide chain-termination method [16] with the Applied Biosys- 
terns automated DNA sequencer, combined with manual DNA se- 
quencing with the Sequenase version 2.0 sequencing kit (from USB). 
DNA and deduced amino acid sequences were analyzed by the 
MacYector and IntelliGenetics DNA-sequence software programs. 
2.3. RT-PCR and Southern analysis 
RT-PCR (reverse transcriptase-polymerase chain reaction) was util- 
ized for detection of ACT mRNAs in bovine adrenal medulla, pituitary, 
and liver. RT-PCR with poly(A+)RNA was performed with the Gene- 
Amp thermostable rTth reverse transcriptase RNA PCR kit (Perkin 
Elmer), according to the manufacturer's protocol. PCR primers 
A (sense) and B (antisense) complementary to the AM ACT cDNA 
sequence were 5'-GGAAGAACGTCTTGAGAATCATTGTGC- 
8 
50 i00 
CGGCACGAGC CAACTTCAGG GATTCTGAAG CTGCCAGGAG TCTAATAAAT GACTATGTGA GAATAAAAC CCAGGGGAAA AAAGAAGAGC TGTTCAAGTA 
A laArgA la  AsnPheArg  AspSerGlu  A laA laArgSer  Leu I leAsn  AspTyrVa l  LysAsnLysThr  G lnGlyLys  LysGluGlu  LeuPheLysTyr  33 
150 200 
CCTTTCCCCG AGAACAGAGT TGGTGCTAGT GAATTACATC TACTTTAAAG CCCAATGGAA GACCCCCTTT GACCCCAAAC ACACTGAGCA GGCAGAGTTC 
LeuSerPro  ArgThrGlu  LeuValLeuVal  AsnTyr I le  TyrPheLys  A laGlnTrpLys  ThrProPhe AspProLys  H isThrGluGln  A laGluPhe 66 
250 300 
CACGTGAGCG ACAACAAGAC GGTGGAGGTG CCCATGATGA CCCTTGACCT GGAAACCCCT ACTTCCGGG ACGAGGAGCT GGGCTGCACG CTGGTGGAGC 
HisValSer  AspAsnLysThr  Va lG luVa l  ProMetMet  ThrLeuAspLeu GluThrPro  TyrPheArg AspGluGluLeu  GlyCysThr  LeuValGlu 99 
350 400 
TCACGTACAC CAGCAACGAC AGCGCCCTCT TCATCCTCCC CGACGAGGGC AAAATGCGGG ACCTGGAAGC CAAGCTGACC CCGGAGACGC TGACGAGGTG 
LeuThrTyrThr  SerAAg__nAsp SerAlaLeu Phe I leLeuPro  AspGluGly  LysMetArg  AspLeuGluA la  LysLeuThr  ProGluThr  LeuThrArgTrp 133 
450 500 
GCGAAACTCC CTGCAGCCCA GACGAATACA TGAACTCTAC CTGCCAAAAT TTTCCATCAA AAGCAACTAT GAACTGAATG ACATCCTCTC CCAGCTGGGC 
ArgAsnSer  LeuGlnPro  ArgArg I leHis  G luLeuTyr  LeuProLys  PheSer I leLys SerAsnTyr  G luLeuAsn  Asp I leLeuSer  GlnLeuGly 166 
550 600 
ATTAGGAAAA TATTTGCCAA CGCTGACTTG TCAGGAATCA CAGGGACCGC GGACCTGGTA GTCTCCCAGG TGGTCCACGG CGCTGCGCTG GACGTGGACG 
I leArgLys I lePheAlaAsn A laAspLeu SerGly I le  ThrG lyThrA la  AspLeuVal  Va lSerG ln  Va lVa lH isG ly  A laA laLeu AspValAsp 199 
* 650 Pr imer A 700 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  > 
AGGAGGGCAC GGAAGGAGCT GCTGCCACGG AATCAGCAT GGAAAGAACG ATCTTGAGAA TCATTGTGCG TGTCAACAGG CCCTTCCTGA TTGCCATAGT 
GluGluGlyThr  G luGlyA la  A laA laThr  G ly I leSerMet  G luArgThr  I leLeuArg I le I leVa lArg  Va lAsnArg  ProPheLeu I leAlaI leVal  233 
750 800 
TCTCAAAGAC ACCCAGAGCA TCATCTTTTT GGGGAAAGTC ACCAACCCCA GTGAAGCCTAG AGCTCCGCTC TGAGCTGTGG GTCCCCTCCC TAAGGAAAAG 
LeuLysAsp ThrGlnSer  I le I lePheLeu GlyLysVal  ThrAsnPro  SerGluAla***  252 
850 900 
< .... 
GGTGCGCAGG TCCTGGGTGC AGCCTGGCCC CTGGGCACTG AGGATCCACC CTGCCTGTCC CCACCTGCTC ACCTCTGGGG AGGTGACAGG GACTCTGCTG 
Pr imer B 950 i000 
. . . . . . . . . . . . . . . . . . . . . . . . .  
GGAGCTCCCC ATGCACAGGG AGTCTGTGTC CGGGTCACAG GGAGACTCTG AAACCTCTCA CAGCAATAAA GCACTTTCCT CGGAAAAAAA AAAAAAAAAA 
AAA 
b Primer C 50 i00 
. . . . . . . . . . . . . . . . . . . . . . . . . . .  > 
GGCACGAGTC TCCCAGATGG GCATTAAGAA AATATTCACC GACGCTGACC TGTCAGGAAT CACAGGGACC GCGGACCTGG TAGTCTCCCA GGTGGTCCAC 
AlaArgVal  SerGlnMet Gly I leLysLys I lePheThr AspAlaAsp LeuSerGly I le  ThrGlyThr A laAspLeu Va lVa lSerGln  ValValHis 33 
150 * Pr imer D 200 
< . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
GGCGCTGCGC TGGACGTGGA TGAGGAGGGC ACGGAAGGTG CTGCTGCCAC GGGAATCGGC ATAGAAAGAA CGTTCTTGAG AATCATTGTG CGTGTCAACA 
GlyAlaAla LeuAspValAsp G luGluGly  ThrGluGly  A laA laA laThr  G ly I leGly  I leGluArg ThrPheLeuArg I leI leVal ArgValAsn 66 
250 300 
GGCCCTTCCT GATTGCCGTA GTTCTCAAAG ACACCCAGAG CATCATCTTT TTGGGGAAAG TCACCAACCC CAGTGAAGCC TAGAGCTCCG CTCGAGCTGT 
ArgProPheLeu I leAlaVal ValLeuLys AspThrGlnSer  I le I lePhe LeuGlyLys Va lThrAsnPro  SerGluAla *** 93 
350 400 
GGGTTCCCTC CCTAAGGAGC AGGGTTCCCA GATCCCTGGG TGCAGCCTGG CCCCTGGGCC CTGAGAATCC ACTCTGCCTG CCCCCACCTG CTCACCACTG 
450 500 
GAGAGGTGAC AGTGACTCTG CTGGGAGCTC TACATGCACA GGGAGTCTGT GTCCGGGTCA CAGGGAGACT CTGAAACCTC TCACAGCAAT AAAGCACTTT 
CCTCGGT 
Fig. 1. Nucleotide and deduced primary sequence of cDNAs isolated from bovine adrenal medulla (a) and bovine pituitary (b). The asterisk (*) 
indicates the predicted Pt active-site residue. Potential Asn-Xaa-Thr(Ser) glycosylation sites are indicated by the underlined Asn. Consensus 
polyadenylation sequences are underlined. Nucleotides are numbered above the base sequences, and amino acids are numbered in the right hand 
margin. Arrows indicate the positions of primers A, B, C, and D used in RT-PCR in Fig. 4. 
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GTG-Y and 5'-ACTCCCTGTGCATGGGGAGCTCCCAGCA-3', 
respectively. PCR primers C (sense) and D (antisense) complementary 
to the Pit-ACT cDNA sequence were 5'-CGAGTCTCCCAGATGG- 
GCATTAAGAA-Y and 5'-CCTGTTGACACGCACAATGATTCT- 
CAAGAACG-3', respectively. First strand cDNA synthesis utilized 0.2 
tg  poly(A+) RNA and antisense primer (B or D, at 0.15 tM)  with the 
rTth DNA polymerase in the presence of MnC12 (according to the 
protocol by Perkin Elmer). PCR amplification of these cDNAs was 
then conducted by addition of MgCI2 and sense primer (A or C, at 0.15 
tiM), and 35 PCR cycles, each cycle consisting of 1 min at 94°C, 1 min 
at 65°C, and 1 min 70°C, and a final step at 70°C for 7 min. PCR 
reaction products were analyzed by DNA agarose (2.5%) gel electro- 
phoresis, as well as Southern blot analysis with 32P-labelled (by nick- 
translation) AM ACT cDNA as probe. Filters for Southern blot hy- 
bridization were hybridized with riP-labelled AM ACT in 1% SDS, 10% 
dextran sulfate, 1.0 M NaC1 overnight at 65°C. Filters were washed 
twice in 2x SSC at room temperature for 20 min, twice in 2x SSC 
containing 1% SDS at 65°C for 30 min, twice in 0.1x SSC at room 
temperature for 20 min, and subjected to autoradiography. 
3. Results and discussion 
3.1. Molecular cloning of  ACT cDNAs from bovine adrenal 
medulla and pituitary 
Screening of bovine AM and Pit cDNA libraries (1 x 106 
recombinants)  with the bovine liver L-1 ACT cDNA (clone 
pHHKl l )  [1], resulted in the isolation of partial ACT-like 
cDNAs  that possess the reactive-site domain that is character- 
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Fig. 2. Comparison of primary sequences deduced from bovine adrenal medulla, pituitary, and liver cDNAs. Comparison of ACT primary sequence 
homologies are illustrated for adrenal medulla (b. AM ACT), pituitary (b. Pit ACT), liver isoforms L-1 and L-2 (b. L-1 ACT and b. L-2 ACT, 
respectively) [9], as well as human liver ACT (h. L ACT) [19]. The position of the predicted P1 residues is indicated by the asterisk (*). Dots represent 
identical residues; dashes indicate gaps or no sequence. Possible asparagine (N) glycosylation sites for b. AM ACT, b. Pit ACT, b. L-1 ACT, b. L-2 
ACT, and h. L ACT are indicated by the symbols #, +, @, ^ , and &, respectively. 
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istic of serpin protease inhibitors. One positive clone was iso- 
lated from each library, and clones were designated as 
pHHK13 for the AM ACT eDNA (AM ACT eDNA), and 
pHHK14 for the Pit ACT eDNA (Pit ACT cDNA). The obser- 
vation that only one clone was isolated from each eDNA li- 
brary indicated a relatively low abundance of these neuroendo- 
crine ACT mRNAs. This prediction was confirmed by multiple 
attempts to obtain full-length clones through rescreening 
cDNA libraries with the liver ACT as probe, RT-PCR with 
different primers in Y-RACE of isolated mRNA, and PCR of 
eDNA libraries. Detection of AM and Pit ACT mRNAs by 
PCR but not by Northern blots (section 3.3.) also suggests low 
abundance of mRNA. Importantly, however, these partial 
ACT cDNA clones indicate the expression of novel ACT 
isoforms in neuroendocrine tissues. 
The determined nucleotide sequences and deduced primary 
sequences of these clones (Fig. 1) indicated that the AM ACT 
eDNA of h0 kb possessed an open reading frame of 252 amino 
acids, and the Pit ACT eDNA of 0.5 kb contained an open 
reading frame of 93 residues. Potential glycosylation sites of 
Asn-Xaa-Ser(Thr) [17] were present within the deduced pri- 
mary sequence of AM ACT at residues #21, 71,105, and 248, 
and were present within the deduced primary sequence of Pit 
ACT at residue #89. 
Comparison of deduced primary sequences of the AM and 
Pit ACT cDNAs with the bovine liver L-1 and L-2 ACT 
cDNAs (encoded by clones pHHK11 and pHHK12, respec- 
tively, isolated by this laboratory [9]) indicated that these four 
ACT-like proteins possess varying degrees of homology (Fig. 
2). The AM, Pit, and L-1 ACT isoforms share high degrees of 
homology with one another of 88 98%. However, these three 
ACT isoforms - AM, Pit, and L-1 - shared a lower degree of 
homology with the L-2 ACT of 67%, 53%, and 58%, respec- 
tively. Evidently, the identified neuroendocrine ACT cDNAs 
resemble the L-1 ACT more closely than the L-2 ACT. In 
P6 P5 P4 P3 P2 P1 P I 'P2 'P3 'P4 'P5 'P6 '  
b .AM ACT G I S _M E R T I L R ~ I 
b. P i t  ACT  G _I G I E R T F L R I _I 
b .L - i  ACT  G I S M E R T I S R I I 
b. TI  S R E R R T I _R ~ I 
b .L -2  ACT V V M A T S S - L L H _T 
b. EI V V M A T L _S V L L _H T 
h. L ACT V K I T L L S A L V E T 
m. cont.  I G G I R K A I L P A V 
Fig. 3. Alignment of the reactive-site domains among bovine ACT 
isoforms, human ACT, and mouse contrapsin. The reactive-site do- 
mains from P6 to P~ are compared for bovine adrenal medulla ACT 
(AM ACT), pituitary ACT (Pit ACT), liver ACT forms L-1 and L-2 
(L-1 ACT, and L-2 ACT), bovine trypsin inhibitor (b. TI), bovine 
elastase inhibitor (b. EI), human liver ACT (h. L ACT), and mouse 
contrapsin (m. contrapsin). The alignments are arranged into groups 
possessing optimum homology. The identical residues within the same 
group are underlined. The arrow indicates predicted cleavage sites 
between P~ P~. 
a 
L1  23  456  
<-284 bp 
<o190 bp 
b 
123 456 
<- 284 bp 
<- 190 bp 
Fig. 4. RT-PCR and Southern analysis of ACT mRNAs. (a) Detection 
of AM and Pit ACT mRNAs by RT-PCR. RT-PCR with primers A/B 
complementary to the AM ACT cDNA is shown by ethidium bromide 
staining of DNA agarose gels (2.5%) (lanes 1-3) using poly(A+)RNA 
templates from bovine adrenal medulla (l ne 1), bovine liver (lane 2), 
and bovine pituitary (lane 3). RT-PCR with primers C/D complemen- 
tary to the Pit ACT cDNA (lanes 4-6), utilized poly(A+)RNA templates 
from bovine adrenal medulla (lane 4), bovine liver (lane 5), and bovine 
pituitary (lane 6). Standards from BRL's 1 kb ladder (lane L) shown 
are 1000, 510, 396, 344, 298, 220, 2 1, 154 and 134 bp. Relative posi- 
tions of primers A-D with respect to AM and Pit ACT cDNAs are 
illustrated in Fig. la,b. (b) Southern analysis of RT-PCR of ACT 
isoforms. RT-PCR reactions in Fig. 4a were assessed in Southern blots 
with AM ACT eDNA as probe (as described in section 2). 
addition, the bovine liver L-1 and L-2 forms, AM, and Pit 
isoforms of ACT share approximately 55-65% homology with 
the human liver ACT. 
3.2. Analysis of  reactive site domains of ACT isoforms 
The reactive site domains of the deduced primary sequences 
of the bovine neuroendocrine and liver ACT cDNAs were 
compared to the bovine plasma trypsin and elastase inhibitors 
[18], human liver ACT [13], and mouse contrapsin (the mouse 
counterpart of human or bovine liver ACT) [19]. Alignment of 
homologous sequences at the P6 to P6' positions of the reactive 
site domains indicated two subgroups of bovine ACT reactive 
sites that differ from human ACT and mouse contrapsin (Fig. 
3). The first group is composed of the AM, Pit, and L-1 ACTs, 
and the bovine plasma trypsin inhibitor (TI). These serpins 
possess a typical consensus equence for P6 to P6' residues 
similar to IGIERTILRII .  The second group consists of the L-2 
ACT and the bovine plasma elastase inhibitor (EI); these two 
serpins possess a similar reactive site sequence for P6 to P6' of 
VVMATXSXLLHT. The bovine ACT reactive site sequences 
clearly differ f om those of human ACT and mouse contrapsin. 
It is important o note the differences in the proposed P1 
residues within the bovine ACT reactive sites (Fig. 3). The P~ 
residue of the serpin usually parallels the cleavage specificity of 
the target protease for its peptide substrate, with PI-P/ indicat-  
ing the cleavage site. The isoforms of ACT from adrenal 
X-R. Hwang et al./FEBS Letters 368 (1995) 471~476 
Table 1 
Homology (~f RT-PCR primers to ACT isoforms 
475 
Primer Sequence (5">3') ACT isoform Percent homology among primer pairs 
A GGAAAGAACGATCTTGAGAATCATTGTGCGTG AM/AM 100% 
A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Pit/AM 97 
. . . . . . . . . . . . . .  c . . . . . . . . . . . . . . . . .  L-I/AM 97 
- - CT-CCT-ATCAC-CTTGCA- -CGC-AAC - - L-2/AM 62 
ACTCCCTGTGCATGGGGAGCTCCCAGCA AM/AM 100% 
. . . . . . . . . . . . . . . . . . . . . . . . . . . .  P i t /AM 100 
CTA . . . . . . . . . . .  TA . . . . . . . . . . . .  L-l/AM 81 
T- TTTA-T - - -TGTTCT-  TGGC-  - -AGA L-2/AM 25 
CGAGTCTC CCAGATGGGCATTAAGAA Pit/Pit 100% 
ATCC . . . . . . .  C . . . . . . . . . .  G- - - AM/Pit 77 
ATCC . . . . . . . .  C . . . . . . . . . . .  G- L-i/Pit 77 
ATCC-T . . . . . .  C . . . .  T- -C--G--  L-2/Pit 65 
CCTGTTGACACGCACAATGATTCTCAAGAACG Pit/Pit 100% 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T-- AM/Pit 97 
. . . . . . . . . . . . . . . . . . . . . . . . .  G . . . . . .  L-l/Pit 97 
. . . . . . . .  A-  -TG-  - -G -T -GCG-GTGC- -GA L-2/Pit 56 
D 
Relative positions of primers A, B, C, and D to AM and Pit cDNAs are shown in Fig. la,b. Dashes indicate the same base sequences of ACT DNAs 
compared with the primer sequence. 
medulla and pituitary possess Arg as the proposed P1 residue, 
suggesting that these ACTs may inhibit proteases cleaving at 
Arg residues. The predicted P1 residue as Arg for these ACT 
isoforms is consistent with the known cleavage specificity of 
prohormone processing enzymes for basic residues [2-5]. Evi- 
dence supporting a possible role of neuroendocrine ACTs in 
controlling prohormone processing enzymes has been recently 
demonstrated in our studies showing inhibition of the 'pro- 
hormone thiol protease' (PTP) by the pituitary ACT-like pro- 
tein [8]. Furthermore, purified adrenal medulla ACT-like pro- 
tein inhibits PTP and the subtilisin-like PCI/3 and PC2 
(PC = prohormone convertase) prohormone processing en- 
zymes with differential potencies [20]. 
Most of the liver ACTs [9,13,18] from several species differ 
in their predicted P1 residues compared to the AM and Pit 
ACTs (Fig. 3). The two bovine liver isoforms of ACT (L-1 and 
L-2) possess Arg or Ser as predicted Pl residues, respectively 
[9]. The human ACT [14,16] and mouse contrapsin [19] contain 
Leu and Lys as P1 residues, respectively. These differences in 
P1 residues uggest hat these isoforms of ACT may possess 
selectivity for inhibiting different arget proteases. It will be 
important to analyze recombinant ACT isoforms in functional 
protease inhibitory assays. 
3.3. RT-PCR analysis of ACT rnRNAs 
RT-PCR and Southern blotting were used to determine the 
presence of AM and Pit ACT mRNAs in bovine adrenal me- 
dulla, pituitary, and liver, since these mRNAs were not detected 
by Northern blots. Primers A and B complementary to AM 
ACT were designed to amplify a 284 bp DNA fragment that 
includes the reactive site domain. Analogously, primers C and 
D complementary to the Pit ACT should amplify a 190 bp 
DNA fragment containing the reactive site. RT-PCR with the 
primer pair A/B amplified a284 bp band from adrenal medulla 
and pituitary, but not from liver (Fig. 4a); these bands were 
positive in Southern analysis with the AM ACT cDNA as 
probe (Fig. 4b). This result is consistent with primers A and B 
possessing 97% and 100% homology, respectively, with Pit 
ACT (Table 1). With respect to liver, primers A and B possess 
high homology with L-1 (97% and 81% homology, respec- 
tively), and low homology with L-2 (62% and 25% homology, 
respectively) (Table 1). Thus, if L-2 is the major form of ACT 
in bovine liver, RT-PCR with primers A/B may not generate 
a detectable DNA product, as indicated by results of these 
experiments (Fig. 4). 
Primers C/D complementary to the Pit ACT cDNA possess 
high homology to both cloned AM and L-1 ACT cDNAs. 
Thus, RT-PCR would be predicted to generate a 190 bp DNA 
fragment from adrenal medulla, pituitary and liver. However, 
results indicate production of the 190 bp band from pituitary 
and liver, but not from adrenal medulla (Fig. 4). It is possible 
that small differences in nucleotide base sequence at the 5'- and 
3'-end of the primers may not allow RT-PCR of AM ACT 
(Table 1). Another explanation for the lack of RT-PCR prod- 
uct from adrenal with primers C/D is based on our finding by 
Western blots of three distinct bands of ACT immunoreactivity 
in adrenal medulla [20], suggesting three isoforms of ACT. If 
the AM ACT cDNA obtained in this study is one of the minor 
isoforms of ACT in adrenal medulla, it may not be detected by 
RT-PCR, as shown by results of Fig. 4. 
In conclusion, molecular cloning has revealed the presence 
of unique isoforms of ACT in the neuroendocrine tissues of 
bovine adrenal medulla and pituitary. These ACTs possess 
novel reactive-site domains compared to previously identified 
ACT serpin protease inhibitors. Of interest is the finding that 
the AM and Pit ACT isoforms possess Arg as the predicted PI 
residue. Prohormone processing enzymes, which are colocal- 
ized with ACT immunoreactivity in adrenal medulla nd pitui- 
tary [8,20], possess pecificity for cleavage at paired basic resi- 
dues that include cleavage at Arg residues. The possibility that 
the neuroendocrine ACTs may inhibit prohormone processing 
enzymes should be examined in future studies. It will be impor- 
tant to determine the roles of ACT isoforms in neuroendocrine 
function. 
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